Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420784
Status:
COMPLETED
Last Update Posted:
2014-08-05
First Post:
2007-01-08
Brief Title:
A Study of Telaprevir VX-950 Pegasys and Copegus in Hepatitis C PROVE3
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Study Overview
Official Title:
A Phase 2 Study of Telaprevir VX-950 in Combination With Peginterferon Alfa-2a Pegasys and Ribavirin Copegus in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The PROVE3 trial is a partially double blinded randomized Phase 2 research study of an investigational drug Telaprevir VX-950 or Placebo with Pegylated Interferon Alfa 2a Peg-IFN-alfa-2a Pegasys and Ribavirin RBV Copegus in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response SVR with a previous treatment of interferon therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None